Table 2.
Demographic and clinical characteristics of anti-HCV–negative, HIV-infected subjects.
| Characteristic | FRAM study (n = 869) | Bonacini et al. [13] (n = 124) | George et al. [15] (n = 99) | Hall et al. [16] (n = 82) |
|---|---|---|---|---|
| Sex | ||||
| Men | 640 (74) | 111 (90) | 82 (83) | 72 (88) |
| Women | 229 (26) | 13 (10) | 17 (17) | 10 (12) |
|
| ||||
| Ethnicity | ||||
| African American | 303 (35) | 21 (17) | 5 (5) | 36 (44) |
| Hispanic | 80 (9) | 65 (52) | 2 (2) | 6 (7) |
| Other | 18 (2) | 6 (5) | 9 (9) | 3 (4) |
| White | 467 (54) | 32 (26) | 83 (84) | 37 (45) |
|
| ||||
| Age, median years (IQR) | 41.0 (36.0–48.0) | 37.0 (30.5–45.0 | 38.0 (32.0–44.0) | 42.2 (36.1–49.4) |
|
| ||||
| Any history of IDU | 48 (6) | 9 (7) | 10 (10) | 26 (32) |
|
| ||||
| CD4 cell count, median cells/μL (IQR) | 380 (226–561) | 86 (14–257) | 212 (68–427) | 335 (230–522) |
|
| ||||
| CD4 cell count <200 cells/μL | 187 (22) | 85 (71) | 45 (45) | 19 (23) |
|
| ||||
| HIV RNA level per 1000 copies/mL, median copies/mL (IQR) | 0.4 (0.4–10.4) | 81.1 (34.4–225.9) | 35.9 (9.0–164.9) | 14.0 (0.9–75.0) |
|
| ||||
| ALT, median U/L (IQR) | 25.0 (17.0–38.0) | 82.5 (43.0–182.0) | 23.0 (16.0–32.0) | 22.0 (17.0–32.0) |
|
| ||||
| ALT level greater than the upper limit of normala | 178 (21) | 89 (73) | 16 (16) | 10 (12) |
|
| ||||
| HCV RNA level per 1000 IU/mL, median IU/mL (IQR) | 2313.4 (1.4–7119.1) | NA | NA | 10426.3 (4075.1–16215.9) |
NOTE. Data are no. (%) of patients, unless otherwise indicated. ALT, alanine aminotransferase; anti-HCV, hepatitis C virus antibody; FRAM, Fat Redistribution and Metabolic Change in HIV infection; HCV, hepatitis C virus; IDU, injection drug use; IQR, interquartile range; NA, not available.
a
Defined by the central laboratory of the FRAM study.